DAOA/G72 predicts the progression of prodromal syndromes to first episode psychosis by Mössner, Rainald et al.
ORIGINAL PAPER
DAOA/G72 predicts the progression of prodromal syndromes
to ﬁrst episode psychosis
Rainald Mo ¨ssner Æ Anna Schuhmacher Æ Michael Wagner Æ Boris B. Quednow Æ Ingo Frommann Æ
Kai-Uwe Ku ¨hn Æ Sibylle G. Schwab Æ Marcella Rietschel Æ Peter Falkai Æ Wolfgang Wo ¨lwer Æ
Stephan Ruhrmann Æ Andreas Bechdolf Æ Wolfgang Gaebel Æ Joachim Klosterko ¨tter Æ Wolfgang Maier
Received: 29 January 2009/Accepted: 25 August 2009/Published online: 10 September 2009
 Springer-Verlag 2009
Abstract The genetic factors determining the progression
of prodromal syndromes to ﬁrst episode schizophrenia have
remained enigmatic to date. In a unique prospective mul-
ticentre trial, we assessed whether variants at the D-amino
acid oxidase activator (DAOA)/G72 locus inﬂuence pro-
gression to psychosis. Young subjects with a prodromal
syndrome were observed prospectively for up to 2 years to
assess the incidence of progression to schizophrenia or ﬁrst
episode psychosis. Of the 82 probands with a prodromal
syndrome, 21 probands experienced progression to psy-
chosis within the observation period. Assessment of nine
common variants in the DAOA/G72 locus yielded two
variants with the predictive value for symptom progres-
sion: all four probands with the rs1341402 CC genotype
developed psychosis compared with 17 out of 78 probands
with the TT or CT genotypes (v
2 = 12.348; df = 2;
p = 0.002). The relative risk for progression to psychosis
was signiﬁcantly increased in the CC genotype:
RR = 4.588 (95% CI = 2.175–4.588). Similarly, for
rs778294, 50% of probands with the AA genotype, but only
22% of probands with a GG or GA genotype progressed to
psychosis (v
2 = 7.027; df = 2; p = 0.030). Moreover,
haplotype analysis revealed a susceptibility haplotype for
progression to psychosis. This is one of the ﬁrst studies to
identify a speciﬁc genetic factor for the progression of
prodromal syndromes to schizophrenia, and further
underscores the importance of the DAOA/G72 gene for
schizophrenia.
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Introduction
The development of a ﬁrst episode of schizophrenia is
often preceded by prodromal states with variable symp-
toms [22]. The factors determining the progression of
disease from a prodromal state to a psychotic episode are of
great interest [3]. However, little is currently known about
the factors inﬂuencing whether a prodromal proband pro-
gresses to psychosis or remains stable [6]. We hypothesised
that genetic variants play an important role in determining
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tibility genes identiﬁed in the past few years [15], we
focused on a well characterised schizophrenia susceptibil-
ity locus, DAOA/G72, and queried whether variants in this
locus might inﬂuence this progression.
The DAOA/G72 gene was originally discovered during
the analysis of the schizophrenia susceptibility region on
chromosome 13. Fine-mapping of the region on the long
arm of chromosome 13, 13q12–13q34 led to the discovery
of the new gene G72 [4]. Variants in this gene were related
to schizophrenia in Canadian and Russian subjects. The
G72 gene is transcribed in brain, and increased expression
was found in the dorsolateral prefrontal cortex in schizo-
phrenia compared with controls [12]. To assess the func-
tion of this gene, a screen of binding proteins was
performed, which showed that G72 binds to and activates
D-amino acid oxidase. Therefore, G72 was named D-amino
acid oxidase activator (DAOA) [4]. DAOA/G72 is a very
attractive schizophrenia candidate gene also due to the fact
that it is a primate-speciﬁc gene [4]. A recent meta-analysis
of DAOA/G72 in schizophrenia showed highly signiﬁcant
evidence of association between a number of markers in
the DAOA/G72 region and schizophrenia [5]. These
authors concluded that the association ﬁndings for the
DAOA/G72 gene and schizophrenia are amongst the most
compelling in psychiatry. This led us to focus on the
DAOA/G72 gene, since we expected a sufﬁciently large
effect to be visible in a prospective investigation.
The main outcome measure of the present study was
progression to a psychosis, namely the incidences of ﬁrst
episode schizophrenia and ﬁrst episode psychosis. In a
unique prospective multicenter approach combining psy-
chopathology and genetics, prodromal subjects were fol-
lowed for up to 2 years to prospectively identify those
probands who would progress to psychosis. Speciﬁcally,
we assessed here whether common DAOA/G72 variants
might predict the conversion to a psychosis in this pro-
spective multicentre study. We analysed a number of
variants which are located in the coding region of DAOA/
G72, but also variants in the 50 and 30 putative regulatory
regions which are expected to have an important role in the
function and expression of the DAOA/G72 gene.
Materials and methods
Study subjects
The clinical study was conducted at three early detection
and intervention centres. The centres were located at the
Departments of Psychiatry and Psychotherapy at the
Universities of Bonn, Cologne, and Du ¨sseldorf. To aid in
the recruitment of probands with prodromal syndromes,
awareness programmes were put in place for primary and
psychiatric health services, for the relatives of patients with
schizophrenia, and were also aimed to inform youth sup-
port services as well as the general population. The aims of
the programmes were to establish local mental health
networks as well as the facilitation for persons at a risk to
ﬁnd help with the early intervention services. Information
was provided about early symptoms of schizophrenia as
well as about the usefulness of early intervention. Referrals
of probands were from a number of settings, including
from counselling services, youth support services, primary
health care, and mental health professionals [11].
Theclinicalstudyandtheinclusion andexclusioncriteria
are described in more detail elsewhere [1]. Brieﬂy, patients
were eligible for inclusion in the trial if they met the criteria
of the early or late initial prodromal state and did not fulﬁl
exclusion criteria. The early initial prodromal state was
operationally deﬁned by either basic symptoms predicting
psychosis [10] or by a clinically relevant decline of func-
tioningincombinationwithestablishedriskfactors(riskand
decreased functioning) [22]. Basic symptoms required the
presence of one or more of the following symptoms several
times per week during the last 3 months: thought interfer-
ences, thought perseverations, thought pressure, thought
blockages, disturbances of receptive language, decreased
ability to discriminate between ideas and perception or
between fantasy and true memory contents, tendency to
delusion of reference with subject centrism, derealisation,
visual perception disturbances, and acoustic perception
disturbances. Established risk factors were pre- or perinatal
complications or a ﬁrst-degree relative with a lifetime
diagnosis of schizophrenia or a schizophrenia spectrum
disorder. Late initial prodromal state was deﬁned by the
presence of at least one of the following symptoms
appearing several times a week: ideas of reference, odd
beliefs or magical thinking, unusual perceptual experiences,
odd thinking and speech, or suspiciousness or paranoid
ideation; or by the appearance of one of the following
symptomsforlessthan1 weekandresolvingspontaneously:
hallucinations, delusions, formal thought disorder, or gross
disorganised or catatonic behaviour. Probands were only
includedifagedbetween17and42 years.Exclusioncriteria
of note were previous treatment with antipsychotics, present
or past diagnosis of a schizophrenic, schizophreniform,
schizoaffective, delusional, or bipolar disorder, present or
pastdiagnosisofabriefpsychoticdisorderwithadurationof
morethan1 weekorwithinthe last4 weeksregardless ofits
duration, organic brain disease, and alcohol or drug depen-
dence within the last 3 months. During the study, probands
were seen approximately once a month. Progression to ﬁrst
episode psychosis was operationally deﬁned by cut-off
pointsonpositiveandnegativesyndromescale(PANSS)[8]
subscales of 4 or more on hallucinations, 4 or more on
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123delusions and 5 or more on conceptional disorganisation or
formal thought disorder for at least 7 days and meeting
criteria for schizophrenia (ICD-10: F20) or acute schizo-
phrenia-like psychotic disorder (ICD-10: F23.2). The study
was approved by the appropriate ethics committees.
Genotyping
Nine common variants spanning the DAOA/G72 gene
were identiﬁed from the UCSC genome browser (genome.
cse.ucsc.edu). Single-nucleotide polymorphism nomencla-
ture is based on the NCBI dbSNP build 129 (April 2008,
updated June 2008). Moreover, the traditional M nomen-
clature as described by Chumakov et al. [4] is given,
whenever applicable.Venousblood wastaken atstudyentry
and DNA extracted by standard protocols. DAOA/G72
variants were genotyped by allele discrimination using
TaqMan technology; 12.5 ng of DNA was used for TaqMan
SNP genotyping assays on demand, employing the Applied
Biosystems protocol. Following the completion of PCR
reactions,ﬂuorescencewasdeterminedonaTecan384Ultra
reader(TecanUSA,Durham,NC).Theprobeswerelabelled
with carboxyﬂuorescein (FAM), with an excitation wave-
length of 485 nm and an emission wavelength of 535 nm.
VIC-labelled probes employed an excitation wavelength of
535 nm and an emission wavelength of 590 nm.
Statistical analysis
The inﬂuence of DAOA/G72 variants on progression of
symptoms was assessed by v
2 tests, employing SPSS ver-
sion 14.0 (SPSS, Chicago, USA). If cells had an expected
frequency of\5, Monte Carlo simulation based on 10,000
permutations with the start value 92,208,573 was done. The
level of signiﬁcance was set at p\0.05 (two sided). To
correct for multiple testing, the spectral decomposition
method was employed to estimate the number of effective
loci [14, 17]. Age distribution of the proband groups was
assessed by ANOVA. Haplotype block structure was
determined by the solid spine of LD method as imple-
mented in Haploview (Broad Institute, Mass, USA). Hap-
lotype analysis was performed employing the program
Famhap 17 [2]. Famhap 17 yields a global signiﬁcance
value of the haplotype analysis employing the likelihood
ratio test, as well as individual p values for each haplotype.
Individual haplotype p values were subsequently corrected
for multiple testing employing Bonferroni correction.
Results
Eighty-two probands were enrolled in the prospective
study of early prodromal states. They were followed
longitudinally and were assessed for progression to
psychosis. DNA was obtained for subsequent determina-
tion of DAOA/G72 variants. The mean age of the probands
was 26.3 ± 7.1 years. Twenty-one probands experienced a
progression of symptoms to schizophrenia or ﬁrst episode
psychosis. The mean duration for progression to psychosis
was 29.7 weeks (range 2–86 weeks).The mean age of those
patients progressing to psychosis was 24.2 ± 5.0 years and
they were thus on an average slightly younger than those
probands who remained stable (27.0 ± 7.6 years;
F = 3.139; p = 0.083 by Welch test). The gender distri-
bution did not differ between the probands who progressed
and those who remained stable (v
2 = 1.320; df = 1;
p = 0.251).
We then queried whether the likelihood of progression
to psychosis is related to variants of the DAOA/G72 gene.
Two variants were found to have an impact on the pro-
gression to psychosis. Thus, for rs1341402, 20.4% of
probands with the TT genotype and 24.1% of heterozygous
probands (TC genotype) progressed to psychosis (Table 1).
In contrast, all homozygous CC probands progressed to
psychosis. This effect was statistically signiﬁcant
(v
2 = 12.348, df = 2, p = 0.002). This ﬁnding remained
signiﬁcant after the correction for multiple testing with the
spectral decomposition method [14, 17]: with an effective
number of independent marker loci of 5, the signiﬁcance
threshold is p = 0.01. A weaker effect was seen for another
DAOA/G72 variant, rs778294 (M19). For the AA geno-
type, 50% of probands progressed to psychosis (5 out of 10
probands with the AA genotype). In contrast, only 13.2%
of probands with the GG genotype progressed. Heterozy-
gous GA probands experienced a progression to psychosis
in 32.4% of cases. The increased likelihood of progression
for the AA genotype was nominally signiﬁcant
(v
2 = 7.027, df = 2, p = 0.030).
A linkage plot of the nine variants analysed in the 82
prodromal probands is shown in Fig. 1. As can be seen, the
analysed markers segregate into two haplotype blocks.
Markers rs1341402 and rs778294 are located in the same
haplotype block 1. Given a D0 of 0.95 between markers
rs1341402 and rs778294, we constructed a two-marker
haplotype comprising these two variants. Haplotype anal-
ysis of this two-marker haplotype revealed two haplotypes
that had an impact on the progression of prodromal patients
to psychosis (Table 2). Thus, haplotype C–A is present in
35.7% of prodromal patients who progressed to psychosis,
but only in 17.1% of prodromal subjects who remained
stable (p = 0.046; Bonferroni corrected p value). Con-
versely, haplotype T–G is present in 72% of prodromal
subjects who remained stable compared with 50% of pro-
dromal patients who progressed to psychosis (p = 0.031;
Bonferroni corrected p value). Thus, haplotype C–A
increases the susceptibility for progression to psychosis,
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123while haplotype T–G is protective. The global p value for
this haploype analysis was p = 0.047.
When haplotype analysis was performed on all
six markers contained in haplotype block 1, no signiﬁcant
association of the six marker haplotypes, with progression
to psychosis was seen (p = 0.21; likelihood ratio test).
Similarly, haplotype analysis of the markers in block 2 was
not signiﬁcant (p = 0.295; likelihood ratio test).
Next, we assessed whether the positive and negative
syndrome scale (PANSS) scores at study entry were related
to the long-term progression of the disorder. PANSS scores
at study entry were available for 75 out of the 82 study
probands. Positive symptom scores at study entry related
with later progression: those probands who would progress
during the study period had an initial score of 13.53
compared with 10.64 for those probands who remained
stable (F = 9.030; p = 0.004). Negative symptoms and
total PANSS scores also showed an, albeit lesser, inﬂuence.
Thus, probands with later progression had an initial nega-
tive symptom score of 15.0 compared with those who
remained stable (12.34; F = 5.690; p = 0.02). For total
PANSS scores, the respective values were 60.37 (later
progression) and 52.04 (stable probands; F = 6.196;
p = 0.015). Global PANSS scores did not relate to
progression.
Finally, we queried whether DAOA/G72 marker
rs1341402, which had the greatest inﬂuence on progres-
sion, also had an inﬂuence on PANSS scores at study entry.
We found that the probands with the CC genotype, all of
whom later progressed to psychosis, had higher PANSS
scores at study entry compared with the other genotypes
(Table 3). For example, probands with the CC genotype
had a positive PANSS score of 16.5 compared with 11.08
for the TT/CT genotypes (p = 0.025). A similar difference
was found for negative symptoms: 17.25 versus 12.77
(p = 0.033). Moreover, similar ﬁndings were seen in the
haplotype analysis (Table 4). Thus, probands with two
copies of the risk-haplotype C–A had higher positive
symptom scores at study entry (16.50; p = 0.014), and
probands lacking the protective haplotype T–G also had
Table 1 Progression of prodromal probands to psychosis stratiﬁed according to DAOA/G72 genotype
Polymorphism Progression to psychosis according to genotype v
2 p value
rs1935058 TT: 9/26 (34.6%) TC: 7/38 (18.4%) CC: 5/18 (27.8%) 2.182 0.336
rs1341402 TT: 10/49 (20.4%) TC: 7/29 (24.1%) CC: 4/4 (100%) 12.348 0.002**
rs2391191 (M15) GG: 11/34 (32.4%) GA: 7/36 (19.4%) AA: 3/12 (25.0%) 1.532 0.465
rs1935062 AA: 12/39 (30.8%) AC: 6/30 (20.0%) CC: 3/13 (23.1%) 1.084 0.582
rs947267 (M18) AA: 3/20 (15%) AC: 10/41 (24.4%) CC: 8/21 (38.1%) 2.932 0.231
rs778294 (M19) GG: 5/38 (13.2%) GA: 11/34 (32.4%) AA: 5/10 (50.0%) 7.027 0.030*
rs778293 (M22) AA: 7/29 (24.1%) AG: 10/44 (22.7%) GG: 4/9 (44.4%) 1.901 0.387
rs3918342 (M23) CC: 8/23 (34.8%) CT: 10/39 (25.6%) TT: 3/20 (15.0%) 2.198 0.333
rs1421292 (M24) TT: 8/24 (33.3%) TA: 10/40 (25.0%) AA: 3/18 (16.7%) 1.515 0.469
Probands progressing to psychosis/number of prodromal probands with a given genotype are shown
Single-nucleotide polymorphism nomenclature is based on the NCBI dbSNP build 129 (April 2008, updated June 2008)
The traditional M nomenclature as described by Chumakov et al. is also given, whenever applicable
Nominal p values are shown. The nominal signiﬁcance level is set at p\0.05 (the signiﬁcance
Threshold is 0.01 after correction for multiple testing according to Nyholt 2004/Li and Ji 2005)
** df = 2; Monte Carlo simulation yielded a signiﬁcance of p = 0.004
* df = 2; Monte Carlo simulation yielded a signiﬁcance of p = 0.035
Fig. 1 Haplotype block structure of the nine analysed SNPs spanning
the DAOA/G72 gene. The variants segregate into two haplotype
blocks. Haplotype block structure was determined in the 82 prodro-
mal subjects employing the solid spine of LD method as implemented
in Haploview. The location of DAOA/G72 is also shown
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123higher positive (14.56; p = 0.012) and total (63.22;
p = 0.03) PANSS scores at study entry compared with the
other haplotypes (Table 4).
Discussion
This is one of the ﬁrst prospective studies of prodromal
subjects that assess the contribution of genetic variants to
the risk of progression to psychosis. In a multicenter study,
we have identiﬁed probands with a prodromal state and
followed them longitudinally to assess the progression of
symptoms.
Two variants of DAOA/G72 had an important inﬂuence
on the progression of the prodromal subjects. Thus,
all homozygous carriers of the C allele of rs1341402
experienced a progression of symptoms. Similarly, 50% of
probands homozygous for the A allele of rs778294 (M19)
had a progression of symptoms. Therefore, these variants of
DAOA/G72 identify probands at a very high risk of pro-
gression, despite the overall risk of progression of the
probands in the prodromal state being much lower: in the
overall sample, 21 out of 82 study subjects experienced a
transition, corresponding to 25.6% of prodromal subjects.
The relative risk for progression to psychosis was signiﬁ-
cantly increased in homozygous carriers of the rs1341402 C
allele (RR = 4.588, 95% CI = 2.175–4.588, p = 0.003).
The increase in relative risk for subjects homozygous for
the rs778294 (M19) A allele failed to reach signiﬁcance
(RR = 2.250, 95% CI = 0.967–3.987, p = 0.114). These
results indicate that genetic variants in the DAOA gene may
substantially potentiate the risk for subsequent psychosis in
subjects with prodromal symptoms, and may thus aid in
treatment decisions.
Our ﬁndings raise the question of the mechanism by
which DAOA/G72 determines the increased risk for pro-
dromal probands to develop schizophrenia. The DAOA/
G72 gene has since its discovery been described as the
activator of D-amino acid oxidase (DAO) [4]. Given that
this enzyme oxidises D-serine, which is an agonist at
glutamatergic NMDA receptors, DAOA/G72 has been
linked to the glutamate dysfunction hypothesis of schizo-
phrenia. Very recently, G72 has also been linked to a
neurodevelopmental role. Thus, G72 was found to promote
dendritic branching in hippocampal neurons by way of
expression in the mitochondria. This effect was seen only
during the period of active dendritogenesis in synaptically
immature neurons [13]. Moreover, the expression of G72
protein in the amygdala was conﬁrmed [13]. It is currently
not known which effect of the DAOA/G72 gene, namely
the D-serine/glutamate pathway or the mitochondrial
function pathway, is mainly responsible for the role of
DAOA/G72 in schizophrenia. Both mechanisms could
contribute to the structural and functional brain alterations
that may precede the onset of schizophrenia [16, 18, 21].
A meta-analysis of published association studies found
highly signiﬁcant associations between variants of DAOA/
Table 2 Haplotype analysis of the two-marker haplotype rs1341402-
rs778294 of DAOA/G72 in prodromal subjects
Haplotype
(rs1341402-rs778294)
Frequency
in patients
progressing to
psychosis (%)
Frequency
in probands
remaining
stable (%)
p value
#
T–G 50.0 72.0 0.031*
T–A 14.3 9.93 [0.1
C–A 35.7 17.1 0.046*
The global signiﬁcance of this haplotype analysis was p = 0.047
(likelihood ratio test)
# p values are Bonferroni corrected
* p value signiﬁcant after Bonferroni correction
Table 3 PANSS scores at study entry stratiﬁed according to DAOA/
G72 rs1341402 genotype
PANSS scales rs1341402 CC rs1341402 TT/TC p value*
Positive symptoms 16.5 ± 5.06 11.08 ± 3.55 0.025
Negative symptoms 17.25 ± 3.30 12.77 ± 4.27 0.033
Global PANSS score 34.75 ± 7.63 29.47 ± 7.03 0.171
Total PANSS score 68.5 ± 14.47 53.33 ± 12.58 0.047
* Mann–Whitney test with two-sided Monte Carlo signiﬁcance.
10,000 simulations with a start value of 2,000,000 were done
Table 4 PANSS scores at study entry stratiﬁed according to DAOA/G72 two-marker haplotype rs1341402–rs778294
PANSS scales Haplotype T–G p value Haplotype C–A p value
09 19 29 09 19 29
Positive symptoms 14.56 ± 3.81 10.39 ± 3.41 11.48 ± 3.79 0.012 11.35 ± 3.77 10.60 ± 3.12 16.50 ± 3.81 0.014
Negative symptoms 15.11 ± 4.78 12.09 ± 4.20 13.36 ± 4.22 0.148 12.67 ± 4.19 12.96 ± 4.51 17.25 ± 3.30 0.128
Global PANSS score 33.56 ± 5.64 28.21 ± 7.56 30.27 ± 6.71 0.116 29.43 ± 7.12 29.56 ± 7.01 34.75 ± 7.63 0.357
Total PANSS score 63.22 ± 12.18 50.7 ± 12.46 55.12 ± 12.83 0.030 53.46 ± 13.14 53.12 ± 11.76 68.50 ± 14.48 0.075
PANSS scores are given for probands with 0, 1 or 2 copies of each haplotype
p values were calculated by one-way ANOVA
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123G72 and schizophrenia as well as less signiﬁcant evidence
of an association with bipolar disorder [5], although a very
recent meta-analysis showed weaker effects [20]. The
associated markers varied across studies. Thus, it remained
unclear whether the associated markers all reﬂect the same
functional variation or, more likely, multiple functionally
important variants are present in a large region encom-
passing DAOA/G72 [5]. Notably, markers rs778293
(M22), rs3913842 (M23), and rs1421292 (M24) which we
have previously shown to be associated with schizophrenia
[19] show no linkage disequilibrium with the other markers
analysed. This further suggests that there is more than one
functional allele contributing to schizophrenia susceptibil-
ity in the DAOA/G72 region. Interestingly, these three
markers are located more than 50 kb downstream of the
coding region of DAOA/G72. The only other gene in this
area is a hypothetical gene called G30, which is located on
the opposite strand and might provide antisense regulation
of the DAOA/G72 transcript. These three markers are,
therefore, likely to exert effect independent from the other
DAOA/G72 markers. In our study, these three markers did
not inﬂuence progression of prodromal probands, in con-
trast to the markers located in the putative promotor region
or in the coding region of DAOA/G72.
We then queried whether the variants relating to
symptom progression of prodromal patients may be
functional. The variant most strongly associated with the
progression of prodromal subjects is rs1341402. This
variant is located at position -2854 with respect to the
transcription start site. It is, thus, located in the extended
putative promotor region of G72. Because common pro-
motor variants frequently have major inﬂuence on the
expression level of the gene product, rs1341402 is an
excellent functional candidate variant in the promotor
region of G72. The second variant relating to symptom
progression is rs778294 (M19). This variant is situated
15 bp upstream of the 50 end of a protein-coding exon of
G72 [4]. As Chumakov et al. [4] note this variant is part of
the consensus sequence of an acceptor splice site and thus
could potentially alter the splicing of G72. This variant is
in high linkage disequilibrium with the mostly associated
variant rs1341402, with a D0 value of 0.95 (Fig. 1).
A variant that does not relate to symptom progression of
prodromal subjects is rs2391191 (M15). This is a coding
variant of G72, leading to a lysine/arginine exchange.
Because this is a conservative amino acid exchange, it is
not surprising that this variant does not relate to symptom
progression in prodromal subjects.
Progression of prodromal probands to schizophrenia has
previously been investigated with regard to the neuregulin
1 (NRG1) gene. An NRG1 variant was related to pro-
gression to schizophrenia in prodromal probands [9]. The
same variant was implicated in the development of
psychosis in high-risk subjects for psychosis [7]. The
sample size of the study group in these two studies was
similar to the present study; with 67 prodromal probands
[9] and 79 high-risk subjects [7] investigated, respectively,
compared with 82 prodromal probands in the present study.
In conclusion, DAOA/G72 is one of the ﬁrst genes
identiﬁed to inﬂuence the risk of symptom progression of
schizophrenia prodromal probands. Variation in DAOA/
G72 identiﬁed here explains part of the risk of progression.
We anticipate that other genes acting either alone or in
concert with DAOA/G72 and NRG1 will be identiﬁed in
the future to also inﬂuence the risk of progression to
schizophrenia. These other genes may act in the same
pathophysiological pathways as DAOA/G72, or operate in
different pathogenic biochemical pathways. Thus, it may
be feasible in the future to establish a risk proﬁle of pro-
dromal probands according to their combination of risk
alleles and identify those probands in whom a prophylactic
treatment with neuroleptics or other as yet to be discovered
treatment modalities should be instituted immediately to
prevent progression to schizophrenia.
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